Developer docs
API playgroundTry for free, no card

Search company profiles

Lupin Pharma Canada Ltd

Full company profile

uuid004tkpa

Namestring
Lupin Pharma Canada Ltd
Legal namestring
Lupin Pharma Canada Ltd
Websiteurl
lupinpharma.ca
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Lupin Pharma Canada Ltd is the Canadian subsidiary of Lupin Limited, a top-three Indian pharmaceutical group headquartered in Mumbai and founded in 1968. Established in 2014 and headquartered in Longueuil, Quebec with a regional office in Mississauga, Ontario, the Canadian operation employs 37 staff and serves Canadian patients and healthcare professionals across three therapeutic franchises: Gastroenterology, Palliative Care, and Respiratory/Women's Health.

The company markets a differentiated mix of branded specialty products, generics, and a biosimilar. The branded portfolio centers on three in-licensed assets: ZAXINE® (rifaximin 550mg) for hepatic encephalopathy and IBS-D, Relistor® (methylnaltrexone) for opioid-induced constipation, and INTRAROSA® (prasterone 6.5mg vaginal ovule) for postmenopausal vulvovaginal atrophy. The generic portfolio spans cardiovascular (propranolol), anti-infectives (cephalexin, letermovir), respiratory (tiotropium), antiallergics (sodium cromoglicate) and women's health products (oral contraceptives, estradiol). The biosimilar line includes RYMTI® (etanercept) for autoimmune disease. All products are produced, researched or licensed through the parent company's 15 manufacturing sites and 7 research centres.

Lupin Pharma Canada generates revenue primarily through B2B wholesale distribution to Canadian pharmacies and distributors at standard net-30 payment terms with a $2,500 minimum direct-order value, and through licensing/royalty streams tied to its distribution and commercialization agreements with partners such as Salix Pharmaceuticals and Endoceutics. Go-to-market is field-sales-led, targeting gastroenterologists, palliative care specialists, respiratory physicians and women's health prescribers via a dedicated HCP portal, professional community, and the Lupin Genesis patient assistance program. Its products are labelled exclusively for the Canadian market with export prohibited.

Short descriptiontext

Lupin Pharma Canada Ltd is the Canadian subsidiary of India's Lupin Limited, established in 2014 and headquartered in Quebec. It commercializes branded specialty products (ZAXINE, Relistor, INTRAROSA), generics, and a biosimilar across gastroenterology, palliative care, and women's health for Canadian healthcare professionals and patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLongueuil, Canada
HQ citystring
Longueuil
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, branded pharmaceuticals, specialty therapeutics, biosimilar products, patient support programs
Industry3 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Branded Pharmaceutical Sales
TypeOne Time License
Description

Revenue generated from the sale of branded prescription medicines including INTRAROSA, Relistor, and Zaxine to healthcare providers and patients across Canada. Products are distributed through wholesale channels and direct pharmacy fulfillment.

lupinpharma.ca
2Generic Pharmaceutical Sales
TypeOne Time License
Description

Revenue from generic pharmaceutical products including LUPIN-PROPRANOLOL, LUPIN-CEPHALEXIN, LUPIN-LETERMOVIR, NALCROM, and others distributed through standard pharmaceutical supply chains.

lupinpharma.ca
3Licensing and Distribution Partnerships
TypeLicensing Royalties
Description

Revenue through licensing and distribution agreements with partners such as Salix Pharmaceuticals for exclusive Canadian rights to gastroenterology products, and Endoceutics for INTRAROSA commercialization.

lupinpharma.ca
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D, Others
Pricing details1 tier
1B2B pharmaceutical wholesale pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Products are sold to wholesale distributors and pharmacies through standard pharmaceutical pricing with net 30 day payment terms. Minimum order of $2500 for direct orders. Pricing subject to change without notice at time of order receipt.

lupinpharma.ca
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1LUPIN Genesis Patient Support Program
Description

Patient support program offered by Lupin Pharma Canada

lupinpharma.ca
Core offering1 text field

Lupin Pharma Canada Ltd is the Canadian subsidiary of Lupin Limited, established in 2014 and headquartered in Toronto with operations in Montreal. The company markets and distributes a portfolio of branded, generic, and biosimilar prescription pharmaceuticals across four therapeutic franchises — Gastroenterology, Palliative Care, Respiratory, and Women's Health — to Canadian patients through wholesale distribution partners and a dedicated patient support program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • INTRAROSA demonstrated statistically significant beneficial effects (p=0.017 to < 0.0001) at 2 weeks on pH and cell composition, with 52% to 81% of 12-week effects observed by 2 weeks
+1 more record
Product overview1 text field

Lupin Pharma Canada Ltd operates as the Canadian subsidiary of Lupin Limited, offering a diversified portfolio of branded and generic pharmaceutical products. The branded portfolio includes three key innovative products: INTRAROSA® (prasterone vaginal ovule for women's health), ZAXINE® (rifaximin for GI conditions), and Relistor® (methylnaltrexone for opioid-induced constipation). The generic portfolio includes antibiotics (LUPIN-CEPHALEXIN), cardiovascular medications (LUPIN-PROPRANOLOL), respiratory treatments (Lupin-Tiotropium), women's health products (Lupin-Estradiol, JENCYCLA, LAYLAA), antiallergics (NALCROM), antivirals (LUPIN-LETERMOVIR), and others. The biosimilar portfolio includes RYMTI® (etanercept). The company also operates the LUPIN Genesis Patient Support Program for patient assistance. The company focuses on three key therapeutic areas: Gastroenterology, Palliative Care, and Respiratory.

Product and service6 records
1INTRAROSA
CategoryWomen's Health pharmaceuticals
Description

INTRAROSA is a prescription pharmaceutical product commercialized by Lupin Pharma Canada in the Women's Health therapeutic franchise; it is supplied to Canadian pharmacies via wholesale partners for prescribing physicians and their patients.

2ZAXINE
CategorySpecialty pharmaceuticals
Description

ZAXINE is a branded prescription pharmaceutical marketed by Lupin Pharma Canada in Canada; it is supplied to Canadian pharmacies through wholesale distributors.

3Relistor
CategoryPalliative Care / Gastroenterology pharmaceuticals
Description

Relistor is a branded prescription pharmaceutical distributed by Lupin Pharma Canada in Canada; it is sold to Canadian pharmacies through wholesale partners for prescribing physicians and patients.

4RYMTI
CategoryBiosimilar pharmaceuticals
Description

RYMTI is a biosimilar prescription pharmaceutical marketed and distributed by Lupin Pharma Canada in Canada; it is supplied to Canadian pharmacies through wholesale distribution partners.

5Generic pharmaceutical portfolio
CategoryGeneric pharmaceuticals
Description

A portfolio of generic prescription pharmaceuticals sold by Lupin Pharma Canada across its Gastroenterology, Palliative Care, Respiratory, and Women's Health franchises; distributed to Canadian pharmacies through wholesale partners.

6LUPIN Genesis Patient Support Program
CategoryPatient support services
Description

LUPIN Genesis is Lupin Pharma Canada's patient support program that assists Canadian patients and prescribers with access, coverage navigation, and adherence for the company's specialty pharmaceutical products.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Endoceutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-08
Description

Lupin Pharma Canada partnered with Endoceutics to commercialize INTRAROSA (prasterone 6.5mg vaginal ovule) for treatment of postmenopausal vulvovaginal atrophy in Canada. INTRAROSA is Endoceutics' flagship product developed in Quebec, Canada and manufactured in Mont-Saint-Hilaire, Canada. The partnership expands Lupin's women's health portfolio in Canada.

lupinpharma.ca
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2014-09-12
Description

Lupin entered into an exclusive distribution agreement with Salix Pharmaceuticals for Canadian rights to Zaxine (rifaximin) 550mg for hepatic encephalopathy and IBS-D, Relistor (methylnaltrexone) subcutaneous injection for opioid-induced constipation, and other gastroenterology products. The agreement grants Lupin exclusive rights to promote, distribute and market these products in Canada.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Knight Therapeutics is a Canadian specialty pharmaceutical company that in-licenses and commercializes innovative products across Canada and select international markets — closely comparable to Lupin Pharma Canada's licensing-driven model.

2Endoceutics
TypeEmerging player
Description

Endoceutics is the Canadian women's health biotech that developed and manufactures INTRAROSA — Lupin's partner for Canadian commercialization. Comparable as a Quebec-based specialty pharma company targeting women's health with innovative therapies.

TypeDirect peer
Description

Viatris Canada offers a broad portfolio of generics, branded, and biosimilars across multiple therapeutic areas including gastroenterology, women's health, and respiratory — directly comparable to Lupin's diversified portfolio.

TypeDirect peer
Description

Apotex is Canada's largest generic pharmaceutical manufacturer with a broad generics portfolio spanning antibiotics, cardiovascular, women's health, and CNS — directly competing with Lupin Pharma Canada's generic lineup.

5Bausch Health Canada
TypeBroad incumbent
Description

Bausch Health is the parent of Salix and a broad incumbent in Canadian specialty pharma with established gastroenterology, dermatology, and eye-health franchises — overlapping with Lupin's gastroenterology and specialty focus.

TypeDirect peer
Description

Sandoz Canada is the generics and biosimilars arm of Novartis, operating one of the broadest generic and biosimilar portfolios in Canada — a direct peer in both the generic and emerging biosimilars space where Lupin competes with RYMTI.

TypeDirect peer
Description

Salix (a Bausch Health subsidiary) is the originator partner for ZAXINE and Relistor and grants Lupin exclusive Canadian rights to these gastroenterology and palliative care products. Directly comparable as a U.S.-based specialty pharma company focused on gastroenterology.

TypeDirect peer
Description

Teva Canada is one of the largest generic and specialty pharmaceutical companies in Canada, offering both branded and generic products across multiple therapeutic areas including gastroenterology, women's health, and central nervous system — directly overlapping with Lupin's portfolio.

TypeDirect peer
Description

Pharmascience is a major Canadian-owned pharmaceutical company offering generics and specialty products across multiple therapeutic categories, competing head-to-head with Lupin in the Canadian market.

TypeDirect peer
Description

AA Pharma is a Canadian specialty generic pharmaceutical company focused on niche therapeutic areas, offering a comparable specialty generics approach to Lupin Pharma Canada.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lupin Pharma Canada Ltd

Specialty Pharmaceuticalslupinpharma.ca

Lupin Pharma Canada Ltd is the Canadian subsidiary of India's Lupin Limited, established in 2014 and headquartered in Quebec. It commercializes branded specialty products (ZAXINE, Relistor, INTRAROSA), generics, and a biosimilar across gastroenterology, palliative care, and women's health for Canadian healthcare professionals and patients.

What Lupin Pharma Canada Ltd does

Lupin Pharma Canada Ltd is the Canadian subsidiary of Lupin Limited, a top-three Indian pharmaceutical group headquartered in Mumbai and founded in 1968. Established in 2014 and headquartered in Longueuil, Quebec with a regional office in Mississauga, Ontario, the Canadian operation employs 37 staff and serves Canadian patients and healthcare professionals across three therapeutic franchises: Gastroenterology, Palliative Care, and Respiratory/Women's Health.

The company markets a differentiated mix of branded specialty products, generics, and a biosimilar. The branded portfolio centers on three in-licensed assets: ZAXINE® (rifaximin 550mg) for hepatic encephalopathy and IBS-D, Relistor® (methylnaltrexone) for opioid-induced constipation, and INTRAROSA® (prasterone 6.5mg vaginal ovule) for postmenopausal vulvovaginal atrophy. The generic portfolio spans cardiovascular (propranolol), anti-infectives (cephalexin, letermovir), respiratory (tiotropium), antiallergics (sodium cromoglicate) and women's health products (oral contraceptives, estradiol). The biosimilar line includes RYMTI® (etanercept) for autoimmune disease. All products are produced, researched or licensed through the parent company's 15 manufacturing sites and 7 research centres.

Lupin Pharma Canada generates revenue primarily through B2B wholesale distribution to Canadian pharmacies and distributors at standard net-30 payment terms with a $2,500 minimum direct-order value, and through licensing/royalty streams tied to its distribution and commercialization agreements with partners such as Salix Pharmaceuticals and Endoceutics. Go-to-market is field-sales-led, targeting gastroenterologists, palliative care specialists, respiratory physicians and women's health prescribers via a dedicated HCP portal, professional community, and the Lupin Genesis patient assistance program. Its products are labelled exclusively for the Canadian market with export prohibited.

Lupin Pharma Canada Ltd firmographics

Firmographics
Name
Lupin Pharma Canada Ltd
Legal name
Lupin Pharma Canada Ltd
Website
https://lupinpharma.ca
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Lupin Pharma Canada Ltd is the Canadian subsidiary of India's Lupin Limited, established in 2014 and headquartered in Quebec. It commercializes branded specialty products (ZAXINE, Relistor, INTRAROSA), generics, and a biosimilar across gastroenterology, palliative care, and women's health for Canadian healthcare professionals and patients.
Ownership category
akta.pro rank

Lupin Pharma Canada Ltd industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)

Keywords

  • Generic pharmaceuticals
  • Branded pharmaceuticals
  • Specialty therapeutics
  • Biosimilar products
  • Patient support programs

Where Lupin Pharma Canada Ltd is headquartered

Location

Headquarters

HQ city
Longueuil
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

Lupin Pharma Canada Ltd business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D, Others

Revenue model

  1. Branded Pharmaceutical Sales: Revenue generated from the sale of branded prescription medicines including INTRAROSA, Relistor, and Zaxine to healthcare providers and patients across Canada. Products are distributed through wholesale channels and direct pharmacy fulfillment.
  2. Generic Pharmaceutical Sales: Revenue from generic pharmaceutical products including LUPIN-PROPRANOLOL, LUPIN-CEPHALEXIN, LUPIN-LETERMOVIR, NALCROM, and others distributed through standard pharmaceutical supply chains.
  3. Licensing and Distribution Partnerships: Revenue through licensing and distribution agreements with partners such as Salix Pharmaceuticals for exclusive Canadian rights to gastroenterology products, and Endoceutics for INTRAROSA commercialization.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B pharmaceutical wholesale pricing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Lupin Pharma Canada Ltd product offering

Product offering

Core offering

Lupin Pharma Canada Ltd is the Canadian subsidiary of Lupin Limited, established in 2014 and headquartered in Toronto with operations in Montreal. The company markets and distributes a portfolio of branded, generic, and biosimilar prescription pharmaceuticals across four therapeutic franchises — Gastroenterology, Palliative Care, Respiratory, and Women's Health — to Canadian patients through wholesale distribution partners and a dedicated patient support program.

Product overview

Lupin Pharma Canada Ltd operates as the Canadian subsidiary of Lupin Limited, offering a diversified portfolio of branded and generic pharmaceutical products. The branded portfolio includes three key innovative products: INTRAROSA® (prasterone vaginal ovule for women's health), ZAXINE® (rifaximin for GI conditions), and Relistor® (methylnaltrexone for opioid-induced constipation). The generic portfolio includes antibiotics (LUPIN-CEPHALEXIN), cardiovascular medications (LUPIN-PROPRANOLOL), respiratory treatments (Lupin-Tiotropium), women's health products (Lupin-Estradiol, JENCYCLA, LAYLAA), antiallergics (NALCROM), antivirals (LUPIN-LETERMOVIR), and others. The biosimilar portfolio includes RYMTI® (etanercept). The company also operates the LUPIN Genesis Patient Support Program for patient assistance. The company focuses on three key therapeutic areas: Gastroenterology, Palliative Care, and Respiratory.

Differentiator

Problem solved

Functional benefit

Brands

  • LUPIN Genesis Patient Support Program: Patient support program offered by Lupin Pharma Canada

Products and services

  • INTRAROSA INTRAROSA is a prescription pharmaceutical product commercialized by Lupin Pharma Canada in the Women's Health therapeutic franchise; it is supplied to Canadian pharmacies via wholesale partners for prescribing physicians and their patients.
  • ZAXINE ZAXINE is a branded prescription pharmaceutical marketed by Lupin Pharma Canada in Canada; it is supplied to Canadian pharmacies through wholesale distributors.
  • Relistor Relistor is a branded prescription pharmaceutical distributed by Lupin Pharma Canada in Canada; it is sold to Canadian pharmacies through wholesale partners for prescribing physicians and patients.
  • RYMTI RYMTI is a biosimilar prescription pharmaceutical marketed and distributed by Lupin Pharma Canada in Canada; it is supplied to Canadian pharmacies through wholesale distribution partners.
  • Generic pharmaceutical portfolio A portfolio of generic prescription pharmaceuticals sold by Lupin Pharma Canada across its Gastroenterology, Palliative Care, Respiratory, and Women's Health franchises; distributed to Canadian pharmacies through wholesale partners.
  • LUPIN Genesis Patient Support Program LUPIN Genesis is Lupin Pharma Canada's patient support program that assists Canadian patients and prescribers with access, coverage navigation, and adherence for the company's specialty pharmaceutical products.

Quantifiable outcome

  • INTRAROSA demonstrated statistically significant beneficial effects (p=0.017 to < 0.0001) at 2 weeks on pH and cell composition, with 52% to 81% of 12-week effects observed by 2 weeks
  • +1 more outcomes

Companies that use Lupin Pharma Canada Ltd

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Lupin Pharma Canada Ltd technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lupin Pharma Canada Ltd partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • EndoceuticscoreStrategic or Co-development Partner · 8 March 2021Lupin Pharma Canada partnered with Endoceutics to commercialize INTRAROSA (prasterone 6.5mg vaginal ovule) for treatment of postmenopausal vulvovaginal atrophy in Canada. INTRAROSA is Endoceutics' flagship product developed in Quebec, Canada and manufactured in Mont-Saint-Hilaire, Canada. The partnership expands Lupin's women's health portfolio in Canada.
  • Salix PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 12 September 2014Lupin entered into an exclusive distribution agreement with Salix Pharmaceuticals for Canadian rights to Zaxine (rifaximin) 550mg for hepatic encephalopathy and IBS-D, Relistor (methylnaltrexone) subcutaneous injection for opioid-induced constipation, and other gastroenterology products. The agreement grants Lupin exclusive rights to promote, distribute and market these products in Canada.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Lupin Pharma Canada Ltd competitors and assessment

Company assessment

Direct peers

  • Knight Therapeutics: Knight Therapeutics is a Canadian specialty pharmaceutical company that in-licenses and commercializes innovative products across Canada and select international markets — closely comparable to Lupin Pharma Canada's licensing-driven model.
  • Viatris Canada (formerly Mylan): Viatris Canada offers a broad portfolio of generics, branded, and biosimilars across multiple therapeutic areas including gastroenterology, women's health, and respiratory — directly comparable to Lupin's diversified portfolio.
  • Apotex Inc. Apotex is Canada's largest generic pharmaceutical manufacturer with a broad generics portfolio spanning antibiotics, cardiovascular, women's health, and CNS — directly competing with Lupin Pharma Canada's generic lineup.
  • Sandoz Canada: Sandoz Canada is the generics and biosimilars arm of Novartis, operating one of the broadest generic and biosimilar portfolios in Canada — a direct peer in both the generic and emerging biosimilars space where Lupin competes with RYMTI.
  • Salix Pharmaceuticals: Salix (a Bausch Health subsidiary) is the originator partner for ZAXINE and Relistor and grants Lupin exclusive Canadian rights to these gastroenterology and palliative care products. Directly comparable as a U.S.-based specialty pharma company focused on gastroenterology.
  • Teva Canada: Teva Canada is one of the largest generic and specialty pharmaceutical companies in Canada, offering both branded and generic products across multiple therapeutic areas including gastroenterology, women's health, and central nervous system — directly overlapping with Lupin's portfolio.
  • Pharmascience Inc. Pharmascience is a major Canadian-owned pharmaceutical company offering generics and specialty products across multiple therapeutic categories, competing head-to-head with Lupin in the Canadian market.
  • AA Pharma Inc. AA Pharma is a Canadian specialty generic pharmaceutical company focused on niche therapeutic areas, offering a comparable specialty generics approach to Lupin Pharma Canada.

Emerging players

  • Endoceutics: Endoceutics is the Canadian women's health biotech that developed and manufactures INTRAROSA — Lupin's partner for Canadian commercialization. Comparable as a Quebec-based specialty pharma company targeting women's health with innovative therapies.

Broad incumbents

  • Bausch Health Canada: Bausch Health is the parent of Salix and a broad incumbent in Canadian specialty pharma with established gastroenterology, dermatology, and eye-health franchises — overlapping with Lupin's gastroenterology and specialty focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Lupin Pharma Canada Ltd social profiles

Digital presence

Lupin Pharma Canada Ltd financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lupin Pharma Canada Ltd leadership team

Management profile

Number of profiles

Profiles2 records

Lupin Pharma Canada Ltd funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lupin Pharma Canada Ltd M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lupin Pharma Canada Ltd

What does Lupin Pharma Canada Ltd do?

Lupin Pharma Canada Ltd is the Canadian subsidiary of Lupin Limited, established in 2014 and headquartered in Toronto with operations in Montreal. The company markets and distributes a portfolio of branded, generic, and biosimilar prescription pharmaceuticals across four therapeutic franchises — Gastroenterology, Palliative Care, Respiratory, and Women's Health — to Canadian patients through wholesale distribution partners and a dedicated patient support program.

Is Lupin Pharma Canada Ltd a public or private company?

Lupin Pharma Canada Ltd is a private company. It is classified as public and is currently operating.

When was Lupin Pharma Canada Ltd founded?

Lupin Pharma Canada Ltd was founded in 2014. It employs 11 to 50 people.

Where is Lupin Pharma Canada Ltd based?

Lupin Pharma Canada Ltd is headquartered in Longueuil, Canada, in the North America region.

How does Lupin Pharma Canada Ltd make money?

Three revenue lines are on record. Branded Pharmaceutical Sales are the primary driver. The others are generic Pharmaceutical Sales and licensing and Distribution Partnerships.

Who are Lupin Pharma Canada Ltd's main competitors?

Direct peers on record are Knight Therapeutics, Viatris Canada (formerly Mylan), Apotex Inc., Sandoz Canada, Salix Pharmaceuticals, Teva Canada, Pharmascience Inc. and AA Pharma Inc.. Endoceutics is listed as an emerging player. Bausch Health Canada is listed as a broad incumbent.

Does Lupin Pharma Canada Ltd have an API?

No public API is recorded for Lupin Pharma Canada Ltd.

What industry is Lupin Pharma Canada Ltd in?

Lupin Pharma Canada Ltd's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
https://www.outlookbusiness.com/Lupin, Tenpoint Therapeutics Enter Into Partnership To Commercialise YUVEZZI – Outlook BusinessLupin Ltd, through its subsidiary VISUfarma BV, has entered into an exclusive licensing agreement with Visus Therapeutics Inc to commercialise the ophthalmic product YUVEZZI in specified European markets. The deal involves a 20 million euro strategic investment in Visus and offers up to 55 million euros in potential milestone payments, bringing the total consideration to 75 million euros.The Times of IndiaLupin arm to commercialise YUVEZZI eye drop across key European marketsLupin Ltd's subsidiary VISUfarma BV has entered into an exclusive licensing agreement with Visus Therapeutics Inc to commercialise the eye drop YUVEZZI in key European markets. The deal involves a 20 million euro strategic investment in Visus and potential milestone payments totaling up to 75 million euros, alongside tiered royalties on net sales.The Times of IndiaLupin arm to commercialise YUVEZZI eye drop across key European marketsLupin Ltd announced that its wholly-owned subsidiary VISUfarma BV has entered into an exclusive licensing agreement with Visus Therapeutics Inc to commercialise the ophthalmic product YUVEZZI in specified European markets. The deal involves a total potential consideration of up to 75 million euros, comprising a 20 million euro strategic investment in Visus and up to 55 million euros in regulatory and commercial milestone payments. This partnership aims to strengthen Lupin's vision care franchise by introducing the first approved once-daily dual-agent eye drop for presbyopia to key territories including the EU, UK, Switzerland, Norway, and Iceland.India InfolineLupin inks pact with China-based Gan & Lee for bofanglutideLupin Ltd has entered into an exclusive license, supply, and distribution agreement with China-based Gan & Lee Pharmaceuticals for bofanglutide, a novel fortnightly GLP-1 receptor agonist. The collaboration grants Lupin exclusive rights to commercialize the drug in India, aiming to expand its presence in the diabetes and obesity segments. Bofanglutide is designed to treat type 2 diabetes and manage weight, with clinical data suggesting efficacy comparable to existing alternatives.JamkaspharmaTop 50 Pharmaceutical Manufacturers in IndiaThe article presents a comprehensive list of the top 50 pharmaceutical manufacturers in India, highlighting their roles in producing branded medicines, generics, and active pharmaceutical ingredients (APIs) for both domestic and international markets. It details specific companies such as Mankind Pharma, Lupin Ltd, Cipla Ltd, and Sun Pharma, noting their product portfolios, manufacturing certifications like WHO-GMP, and global reach.The Times of IndiaLupin inducts Jeffrey Kindler and Alfonso Zulueta as Independent Directors to its boardLupin Ltd has appointed Jeffrey Kindler and Alfonso Zulueta as independent directors to its board. The new members bring extensive experience from their current and previous roles in the healthcare and pharmaceutical sectors, including leadership positions at Pfizer and Interpharma Investments Limited. Lupin's CEO stated that their expertise will help advance the company's growth plans.Business StandardLupin Ltd Share Price Today, 2,181.45, Lupin Ltd Stock Price 2,181.45 on 9th Jan 2026, Lupin Ltd Stock Price Live NSE/BSELupin Ltd shares closed at Rs 2,181.45 on January 9, 2026, marking a 0.36% decline from the previous session. The company reported a consolidated profit of Rs 1,484.83 crore for the quarter ended 2025 against total income of Rs 7,137.51 crore.The Times of IndiaLupin rationalising product portfolio in US to overcome price erosion impact: CEOLupin Ltd is rationalizing its US product portfolio by discontinuing low-margin and negative-margin oral solid generics to counteract price erosion, while transitioning towards complex generics. This strategic shift resulted in a 33% sequential decline in US sales to USD 121 million in the first quarter ended June 30, 2022. The company aims to increase revenue from complex generics to 35-40% within the next two years through its upcoming pipeline.The Times of IndiaLupin Share Price Today, Lupin Stock Price Live NSELupin Ltd. reported a consolidated total income of Rs 7,282.22 Crore for the quarter ended December 31, 2025, representing a 25.09% increase from the same period last year, with net profit after tax reaching Rs 1,180.51 Crore. Foreign institutional investors increased their stake in the company to 21.5%, while domestic institutional holdings decreased slightly to 25.58%. The stock is currently trading at Rs 2,228.70 on the National Stock Exchange, supported by a median analyst target price of Rs 2,400.36.